Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Revelation Biosciences Inc. (NASDAQ: REVB) announced ongoing enrollment in the phase 1b CLEAR study for its lead therapeutic candidate, REVTx-99b, targeting allergic rhinitis, with top-line data expected in the second half of 2022. The company is also in discussions for diagnostic partnerships related to its REVDx-501 rapid home-use diagnostic tool for respiratory viral infections. An investor conference call is scheduled for April 7, 2022, to discuss these developments further.
Revelation Biosciences Inc. (NASDAQ: REVB) announced interim results from its Phase 2b viral challenge study evaluating intranasal REVTx-99a for H3N2 influenza prevention. The study, conducted in Belgium with 30 healthy participants, reported no serious adverse events. However, REVTx-99a failed to meet its primary endpoint, showing no statistically significant difference from the placebo. CEO James Rolke expressed disappointment but emphasized ongoing commitment to other candidates like REVTx-99b for allergic rhinitis management and REVDx-501, a home diagnostic test for respiratory viruses.
Revelation Biosciences (NASDAQ: REVB) announced the completion of dosing and enrollment for its Phase 2b viral challenge study, RVL-VRL01, aimed at evaluating the efficacy of intranasal REVTx-99a for preventing H3N2 influenza in healthy adults. Primary endpoint analysis is expected early Q2 2022, with final data to follow later that quarter. The study aims to reduce influenza viral load, which correlates with symptom severity. Future studies for REVTx-99a may include SARS-CoV-2 and other respiratory viruses.
Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 2022 Virtual Growth Conference from March 28-30, 2022. The company focuses on developing immunologic-based therapies for disease prevention and treatment, including its lead candidate REVTx-99a, designed to combat respiratory viruses like SARS-CoV-2 and influenza. Additionally, Revelation is developing diagnostic solutions such as REVDx-501 for home use to detect respiratory infections. For details, visit www.RevBiosciences.com.
Revelation Biosciences Inc. (NASDAQ: REVB) has completed enrollment and dosing in its Phase 2b viral challenge study (RVL-VRL01) to assess the efficacy of intranasal REVTx-99 against H3N2 influenza in healthy participants. This trial aims to evaluate key metrics such as viral load reduction and symptom duration. Initial primary endpoint data is expected by early Q2 2022. REVTx-99 targets a broad immune response, with plans to extend development to other respiratory viruses, including SARS-CoV-2.
Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 34th Annual Roth Conference from March 13-15, 2022, at The Ritz Carlton, Laguna Niguel in California. Rolke's presentation is scheduled for March 15, 2022, at 8:00 a.m. PT in Blue – Salon 2. A live webcast will be available on the company's website, and a replay will be accessible for 30 days post-event. Revelation is focused on developing immunologic-based therapies, with its lead candidate REVTx-99 targeting respiratory viral infections.
Revelation Biosciences Inc. (NASDAQ: REVB) will present a corporate overview at the BIO CEO & Investor Conference on February 14, 2022, at 10:45 a.m. EST in New York City. CEO James Rolke will host one-on-one meetings throughout the event. The company is focused on developing immunologic therapies, including REVTx-99 for respiratory virus infections and REVTx-200 for enhanced vaccination immunity. Revelation is also advancing REVDx-501, a rapid home diagnostic for respiratory viruses. For details, visit RevBiosciences.com.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a definitive agreement to sell 1,293,126 shares of common stock at $3.00 per share, raising approximately $7.76 million before expenses. The company will also issue warrants for 2,586,667 common shares and pre-funded warrants for 1,239,541 shares. Proceeds will be allocated to advancing its clinical pipeline and for general working capital. The deal is expected to close upon meeting all conditions, including stock exchange approval. Roth Capital Partners is the exclusive placement agent for this offering.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the enrollment of 15 patients in a Phase 2b viral challenge study for the intranasal therapy REVTx-99, targeting H3N2 influenza prevention. This study, conducted in Belgium, aims to evaluate REVTx-99's efficacy against respiratory viral infections by activating an innate immune response. The company expects topline data by Q2 2022.
REVTx-99 may also be applicable for SARS-CoV-2 and other respiratory viruses, addressing a significant need for new therapeutic options amid ongoing viral challenges.
Revelation Biosciences (NASDAQ: REVB) has initiated patient enrollment for a Phase 1b clinical study of REVTx-99, targeting allergic rhinitis and chronic nasal congestion. The randomized, placebo-controlled study aims to assess the safety and tolerability of REVTx-99, with results expected in the first half of 2022. Allergic rhinitis affects approximately 8% of adults and 7% of children in the U.S., increasing asthma risk. REVTx-99 is designed to stimulate the nasal immune system, offering a potential treatment for millions suffering from these conditions.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
